Press release summary
Siemens Healthineers has launched the Innovance D-Dimer 2.0 assay for clinical laboratories assessing suspected venous thromboembolism and other coagulation conditions.
The blood test is CE-marked and has received U.S. Food and Drug Administration 510(k) clearance. It is intended to help exclude deep vein thrombosis and pulmonary embolism when used with a clinical pretest-probability model in outpatients. Outside the United States, the assay also may aid diagnosis and monitoring of hypercoagulable conditions, including disseminated intravascular coagulation, subject to local labeling.
Siemens said the assay uses ready-to-use reagents and controls and is designed for short turnaround times. It is available for hemostasis platforms that include the companyโs CN-3000 and CN-6000 systems. Availability varies by country, with additional market releases expected in October.
Why it matters for laboratories
D-dimer testing frequently enters the laboratory as an urgent order, so reagent handling, analyzer compatibility, and turnaround time directly affect emergency-department workflows. Laboratories considering the assay will still need to verify performance, reference intervals, clinical decision thresholds, and reporting language for their patient population and approved regional indication.
Original source: Siemens Healthineers press release, Sept. 29, 2026.






Leave a Reply